AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04746820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single-center prospective pilot study
Description: fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP
Study NCT02391662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4
Description: Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
Study NCT02391662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 weeks 1,2,3/4
Description: Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: As prescribed
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As prescribed
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching sitagliptin)
Description: Once daily oral administration of placebo (matching sitagliptin).
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching sitagliptin)
Description: Once daily oral administration of placebo (matching sitagliptin).
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching taspoglutide)
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matching taspoglutide)
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Once daily oral administration of 100 mg of sitagliptin.
Study NCT00754988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide
Description: Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
Study NCT04562610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion group
Description: The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
Study NCT04562610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All oral administration group
Description: Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
Study NCT02520661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Transitions Intervention
Description: The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
Study NCT01863238 — intervention group
Intervention type: OTHER
Intervention: Ophthalmologic examinations
Description: Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
Study NCT01863238 — intervention group
Intervention type: DRUG
Intervention: Ivacaftor Exposed
Study NCT04197752 — intervention group
Intervention type: OTHER
Intervention: Regional anesthesia/analgesia techniques
Description: Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
Study NCT03344354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biogel
Description: Sterile surgical gloves used during surgical procedures.
Study NCT03344354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ansell
Description: Sterile surgical gloves used during surgical procedures.
Study NCT03344354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardinal
Description: Sterile surgical gloves used during surgical procedures.
Study NCT03344354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline
Description: Sterile surgical gloves used during surgical procedures.
Study NCT02035501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Tyrosine
Study NCT03848481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV Compound
Description: CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
Study NCT03848481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution contains matching excipients.
Study NCT01420367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole and cephalzolin
Description: IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
Study NCT01420367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole and cephalzolin
Description: IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
Study NCT02035501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00200096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture and questionnaires
Description: Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation.
Study NCT00444574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Study NCT00444574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Study NCT00444574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Study NCT02125513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin and paclitaxel followed by surgery
Study NCT02125513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel followed by surgery
Study NCT03297983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7583
Description: Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
Study NCT03310463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
Study NCT00818025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pocket PATH (Personal Assistant for Tracking Health)
Description: Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
Study NCT01113515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol hydrochloride
Study NCT01113515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study NCT03656133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy fractionation
Description: Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
Study NCT04590235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available.
Study NCT03733587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: GX-I7 25mg/ml/vial
Study NCT03733587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500mg/vial
Study NCT03796494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Straight abutment
Description: This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
Study NCT03796494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slim abutment
Description: This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
Study NCT04493437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
Study NCT00200096 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: placebo acupuncture
Description: During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure.
Study NCT00662220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 25-29 mg/kg/day
Study NCT03519451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Given KickAsh smartphone mobile application
Study NCT03519451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Given Breathe2Relax smartphone mobile application
Study NCT03519451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00462943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.
Study NCT02484365 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: Attach adhesive probe on thumb or index finger
Study NCT01542619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Description: Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
Study NCT01542619 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
Study NCT00662220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 12-15 mg/kg/day
Study NCT05666622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Only routine non-surgical periodontal treatment was applied to the patients.
Description: The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
Study NCT03042793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 peptide vaccine
Description: PD-L1 peptide given subcutaneously with Montanide ISA-51
Study NCT02372903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin
Description: Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
Study NCT03702205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine supplementation
Description: Group taking oral betaine supplementation
Study NCT02758262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation
Study NCT02758262 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive brain stimulation
Study NCT02942056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Cinnamon tablets to treat type 2 DM
Study NCT03702205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (starch) in a similar capsule form.
Study NCT02942056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01151033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent implantation
Description: ProNOVA XR Drug Eluting Stent implantation
Study NCT01110174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD PET/CT
Description: imaging
Study NCT01450930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone intramuscular first
Description: Hydrocortisone intramuscular first
Study NCT01450930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone subcutaneously first
Description: Hydrocortisone subcutaneously first
Study NCT05387720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual diaphragmatic facilitation (PNF) technique
Description: Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs.
Study NCT05387720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigger sensitivity adjustment on mechanical ventilation
Description: The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
Study NCT05387720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique
Description: Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
Study NCT03107663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C Infusion
Description: A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
Study NCT02121782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
Study NCT02121782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
Study NCT01737502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Given PO
Study NCT01737502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01737502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01737502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02883166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: abiraterone
Description: integested with a continental breakfast
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS
Description: JUUL 5%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS
Description: JUUL 5%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study NCT01644422 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
Study NCT01644422 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
Study NCT01644422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard hair follicle transplant
Description: Control arm subject will receive Standard hair follicle transplant
Study NCT00725764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (foretinib)
Description: Multitargeted tyrosine kinase inhibitor